Abstract: Objective :To compare the long-term survival of patients with nasopharyngeal carcinoma (NPC) who were treated with conventional radical radiotherapy (RT) plus Anka capsule (Irrisquin-nones) and radiotherapy alone. Methods :104 patients with histologically proven nasopharyngeal carcinoma were entered.They were randomized to receive Irradiation aid conventional radiotherapy (52 patients) or radiotherapy alone (52 patients). All patients received radical radiotherapy to the nasopharynx and neck with 60Co 1.25 Mev rays.Standardized external was delivered using prescribed tumor doses determined by clinical stage.Irrisquinnones was administered by 140mg/m2/day (70mg/m2 twice daily),to start one day before the onset of radiotherapy and then throughout the course of treatment. Results :After a median follow-up of 5 years, the 5-year overall survival rate for RT group was 66%,RT with Anka group was 67%,but the deference was no statistic (P>0.05). Conclusion :This prospective randomized trial has demonstrated the benefit of Irrisquinones to radiotherapy in the treatment of nasopharyngeal carcinoma. Still it is necessary to follow-up to demonstrate the efficacy of Irrisquninones associated with irradiation increasing the long-term survival rate.